Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorPankaj J. Pasricha
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating pain and for reducing the excitability of nociceptors, comprising administering a TGF-β antagonist. In some embodiments, a TGF-β antagonist is a monoclonal TGF-β neutralizing antibody or a fusion product comprising a monoclonal TGF-β neutralizing antibody, a soluble receptor, an antisense oligodeoxynucleotides (ODNs), a ribozymes, a small inhibitory RNA (siRNA), Smad 6, Smad7, or a small molecule that blocks TGF-β signaling.
Claims18
A method for treating pain, comprising administering to a subject in need thereof a composition comprising a TGF-β antagonist in a therapeutically effective amount to treat pain, wherein said TGF-β antagonist is selected from the group consisting of TGF-β-neutralizing antibodies and fusion proteins thereof.
A method for reducing sensation of pain in a subject experiencing pain, comprising administering to said subject a composition comprising a TGF-β antagonist, wherein said TGF-β antagonist is selected from the group consisting of TGF-β-neutralizing antibodies and fusions proteins thereof, and whereby said TGF-beta antagonist is administered in an amount therapeutically effective to reduce excitability of said subject's nociceptors that have become hyperexcited upon activation by TGF-beta and, thereby, to reduce sensation of said pain.
Dependencies are inferred from the claim text.